Fig. 1

Lovastatin reduced exploration in Ube3a^+/+ and Ube3a^−/+ mice. A, C Lovastatin induced dose dependent decreases in locomotor activity in Ube3a^+/+ mice in both (A) total activity and (C) horizontal activity, over time. Lovastatin, 30 mg/kg and 100 mg/kg reduced (B) total activity and (D) horizontal activity, over time in Ube3a^−/+ mice. E Lovastatin at the 100 mg/kg dose caused a significant reduction in summed total activity across a 30-min session in both Ube3a^+/+ and Ube3a^−/+ mice. Lovastatin, 10 mg/kg and 30 mg/kg also reduced summed total activity in Ube3a^−/+ mice. F Lovastatin, 10 mg/kg and 30 mg/kg reduced summed vertical activity (rearing) in Ube3a^+/+ mice. Ube3a^−/+ mice also displayed reduced summed vertical activity when treated with vehicle or any dose of lovastatin, compared to vehicle treated Ube3a^+/+. * p < 0.05, A-D, two-way repeated measures ANOVA over time by 30 mg/kg of lovastatin and genotype. # p < 0.05, A-D, two-way repeated measures ANOVA over time by 100 mg/kg of lovastatin and genotype. * p < 0.05, E and F, one –way ANOVA for lovastatin, followed by Holm-Sidak post hoc analysis